Press Programme
Press Programme
EASL CONGRESS 2023 PRESS CONFERENCE
OPENING CEREMONY
WEDNESDAY JUNE 21 - 12:00 CEST
PRESS CONFERENCE ROOM, LEVEL 1
Speakers:
Thomas Berg (Chair), Secretary General, EASL
Thomas Reiberger, Associate Professor of Gastroenterology and Hepatology, Medical University of Vienna, Austria
Tetiana Deshko, Director, Programmes, Alliance for Public Health, Ukraine
Jose Willemse, Liver Patients International, the Netherlands
Vlad Ratziu, Institute for Cardiometabolism and Nutrition, INSERM UMRS 1138 CRC, Hospital Pitié-Salpêtrière, Sorbonne Université, France
EASL CONGRESS 2023 PRESS CONFERENCE
SCIENTIFIC HIGHLIGHTS
THURSDAY JUNE 22 - 9:30 CEST
PRESS CONFERENCE ROOM, LEVEL 1
Speakers:
Aleksander Krag (Chair), Vice Secretary, EASL
Stephen Harrison, Visiting Professor of Hepatology, Radcliffe Department of Medicine, University of Oxford
Topic: Primary results from MAESTRO-NASH a pivotal phase 3 52-week serial liver biopsy study in 966 patients with NASH and fibrosis
Time of abstract presentation: Thursday, June 22, 10:30 CEST – Auditorium
Lindsey A Edwards, Honorary Senior Lecturer, King’s College London, Institute of Liver Sciences, School of Immunology and Microbial Sciences, Faculty of Life Sciences and Medicine, London, United Kingdom
Topic: Faecal microbiota transplant restores gut barrier function and augments ammonia metabolism in patients with advanced cirrhosis: a randomized single-blind placebo-controlled trial.
Time of abstract presentation: Friday, June 23, 10:30 CEST – Auditorium
Manasa Alla, Consultant Hepatology & Liver Transplant Medicine, AIG Hospital, India
Topic: Naltrexone is safe and effective in achieving abstinence and reducing alcohol craving in cirrhotic patients: a double-blind randomized placebo-controlled trial.
Time of abstract presentation: Friday, June 23, 10:30 CEST – Auditorium
Julien Calderaro, Associate Professor, University-Hospital Practitioner, Department of Pathology, Henry Mondor Hospital
Topic: Deep learning predicts sensitivity to atezolizumab-bevacizumab from digital slides of hepatocellular carcinoma.
Time of abstract presentation: Saturday, June 24, 11:45 CEST – Auditorium
Milan Mikoviky, Board Director, European Liver Patients Association (ELPA), Macedonia
Maria Buti, Clinical Head of the Hepatology and Internal Medicine Department, Hospital Universitario Vall d’Hebron, Barcelona, Spain
Topic: Long-term efficacy of tenofovir alafenamide in HBeAg-positive and -negative chronic hepatitis B patients treated for up to 8 years in 2 phase 3.
Time of abstract presentation: Friday, June 23, 9:00 CEST – Lehar 4
MEDIA ROUNDTABLE - AI AND LIVER DISEASE
THURSDAY JUNE 22 - 12:00-13:00 CEST
PRESS CONFERENCE ROOM - SCHUBERT 3, 1ST FLOOR
Speakers:
Jakob Kather, Head of Clinical Artificial Intelligence at the Faculty of Medicine and the Faculty of Computer Science, Technical University Dresden, Germany
Julien Calderaro, Associate Professor, University-Hospital Practitioner, Department of Pathology, Henri Mondor Hospital, France
Tom Lüdde, Clinical Director, Department of Gastroenterology, Hepatology and Infectious Diseases, University Hospital Düsseldorf, Germany
LIVER SCANNING AND HEPATITIS TESTING MOBILE UNIT
THURSDAY JUNE 22 - 15:30-16:30 CEST
MESSE WIEN (Outside Foyer A)
